UWPG
DGX icon

Ullmann Wealth Partners Group’s Quest Diagnostics DGX Stock Holding History

Ullmann Wealth Partners Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-183
Closed -$20K – 70
2017
Q2 		$20K Hold
183
– – 0.01% 115
2017
Q1 		$17K Buy
+183
New +$17.4K 0.01% 117

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ullmann Wealth Partners Group's DGX Position: Q3 2017 in Review

Ullmann Wealth Partners Group sold out of Quest Diagnostics (DGX) in Q3 2017, closing a stake of 183 shares — an estimated $20K sold.

Ullmann Wealth Partners Group first reported a position in DGX in Q1 2017 and held it in 2 quarters. The position peaked at $20K in Q2 2017. 616 funds tracked by Wall St. Rank hold DGX as of Q3 2017.

  • Ullmann Wealth Partners Group reported no remaining Quest Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Ullmann Wealth Partners Group sold 183 Quest Diagnostics shares in Q3 2017, an estimated $20K.
  • Ullmann Wealth Partners Group first reported a position in Quest Diagnostics in Q1 2017 and held it in 2 quarters.
  • Ullmann Wealth Partners Group's Quest Diagnostics position peaked at $20K in Q2 2017.
  • 616 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2017.

Based on Ullmann Wealth Partners Group's 13F filing for Q3 2017, filed 14 Nov 2017.